HEALTH PROFESSIONAL · SOURCE READING

Chemotherapy plus immunotherapy

Source: Breast Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 25, 2025 · Captured 2026-09-09.

Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.

Context: Treatment of Metastatic Breast Cancer / Metastatic Triple-Negative Breast Cancer

The standard-of-care treatment for first-line metastatic TNBC with a programmed death-ligand 1 (PD-L1) combined positive score (CPS) of 10 or more is chemotherapy plus pembrolizumab. This was evaluated in the KEYNOTE-355 trial.[56,57]

Source links and citations

Continue within this section

Pembrolizumab →Atezolizumab →

Publication references

Read the original reference and check its publication notices.

PubMed 33278935 · Original source
PubMed 35857659 · Original source

Preserved source evidence · Not medical advice